Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05380635

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Cutaneous T-Cell Lymphoma/Mycosis Fungoides Clinical Trial

Official title:
Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment

Clinical Trial Summary

To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05380635
Study type Interventional
Source Soligenix
Contact
Status Completed
Phase Phase 2
Start date May 9, 2022
Completion date August 16, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03837457 - PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study Phase 2
Completed NCT04702503 - Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) Phase 1
Not yet recruiting NCT06113081 - Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Recruiting NCT06149247 - HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL Phase 2
Terminated NCT03713320 - SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides Phase 2